Vertex Pharmaceuticals Inc. saw its shares surge 12 percent Tuesday after regulators indicated the company’s Hepatitis C drug candidate telaprevir is nearing approval. The news is expected to seal the Cambridge-based company’s planned move to Boston.

View PDF

single-post.php